Individualized Obesity Pharmacotherapy

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT03374956
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Phentermine-Topiramate — DRUG
    Extended Release at dose of 7.5/46 mg oral daily
  • Liraglutide — DRUG
    dose of 3 mg subcutaneous daily
  • Naltrexone/bupropion — DRUG
    Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
  • Phentermine — DRUG
    15-37.5 mg oral daily

Study Details

The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.

Key Dates

Start date
Dec 11, 2017
Status verified
Jun 2023
Primary completion
May 26, 2022
Completion
May 26, 2022

Study Design

Enrollment
193 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention group
    Phenotype-guided pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine plus Exercise
  • Active Comparator: Control Group
    Randomly assigned pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine

Primary Outcome Measure

Change in Total Body Weight [ Time Frame: baseline to 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905-

Find similar trials in Rochester, MN

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies